Abstract
The approval of sipuleucel-T for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer (CRPC) has validated immunotherapy, in general, as a valid approach for this disease. Multiple novel immune based approaches including adenoviral-based vector delivering targeted antigen, DNAbased vaccination, listeria-based vaccination, pox-viral based approach, immune checkpoint blockade and radioimmunoconjugates appear promising. In concert with the development of new immunotherapeutics, the development of optimal intermediate endpoints for clinical efficacy, measures of an optimal immune response and biomarkers predictive for benefit are warranted. We briefly review emerging immunotherapeutic approaches to treat patients with CRPC.
Keywords: Immunotherapy, Castration resistant, Prostate cancer, Sipuleucel-T, Immunotherapy, Novel
Current Cancer Therapy Reviews
Title:Approaches Used in Immunotherapy for Prostate Cancer
Volume: 8 Issue: 4
Author(s): Guru Sonpavde
Affiliation:
Keywords: Immunotherapy, Castration resistant, Prostate cancer, Sipuleucel-T, Immunotherapy, Novel
Abstract: The approval of sipuleucel-T for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer (CRPC) has validated immunotherapy, in general, as a valid approach for this disease. Multiple novel immune based approaches including adenoviral-based vector delivering targeted antigen, DNAbased vaccination, listeria-based vaccination, pox-viral based approach, immune checkpoint blockade and radioimmunoconjugates appear promising. In concert with the development of new immunotherapeutics, the development of optimal intermediate endpoints for clinical efficacy, measures of an optimal immune response and biomarkers predictive for benefit are warranted. We briefly review emerging immunotherapeutic approaches to treat patients with CRPC.
Export Options
About this article
Cite this article as:
Sonpavde Guru, Approaches Used in Immunotherapy for Prostate Cancer, Current Cancer Therapy Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/1573394711208040238
DOI https://dx.doi.org/10.2174/1573394711208040238 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemical Proteomics to Identify Molecular Targets of Small Compounds
Current Molecular Medicine Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment
Current Pharmaceutical Design MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Humoral and Mechanical Cross-Talk in the Vasculature: Perspectives in Vascular Disease
Vascular Disease Prevention (Discontinued) The Hypothalamus and Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Molecular Field Analysis (MFA) and Other QSAR Techniques in Development of Phosphatase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Cellular and Physiological Effects of Ganoderma lucidum (Reishi)
Mini-Reviews in Medicinal Chemistry Receptor Proteins for Nongenomic Actions of Thyroid Hormone
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Extracellular HSP90: An Emerging Target for Cancer Therapy
Current Signal Transduction Therapy Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design 1,2,4-Triazine Chemistry Part III: Synthetic Strategies to Functionalized Bridgehead Nitrogen Heteroannulated 1,2,4-Triazine Systems and their Regiospecific and Pharmacological Properties
Current Organic Synthesis Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design The Role of Obesity in the Development of Polycystic Ovary Syndrome
Current Pharmaceutical Design Anti-inflammatory, Antioxidant and Antiproliferative Activities from Trichilia silvatica (C.DC)
Current Pharmaceutical Biotechnology Prolactin and Blood-Brain Barrier Permeability
Current Neurovascular Research